xmlui.ArtifactBrowser.ConfigurableBrowse.title.metadata.authorArtikkelit"Östergren J"

Viitteet 1-4 / 4

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary

Rydén L; Standl E; Bartnik M; Berghe GV den; Betteridge J; Boer M-J de; Cosentino F; Jönsson B; Laakso M; Malmberg K; Priori S; Östergren J; Tuomilehto J; Thrainsdottir I
Eur Heart J (2007)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering rm (ASCOT-LLA): a multi

Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Östergren J; ASCOT Investigators; Sarti C; Tuomilehto J; Valle T
Lancet (2003)
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)

Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; Östergren J; (Tuomilehto J; Valle T)
Diabetes Care (2005)
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Poulter NR; Wedel H; Dahlöf B; Sever PS; Beevers DG; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; Östergren J; Pocock S; for the ASCOT Investigators; (Tuomilehto J)
Lancet (2005)

Artikkelit - Selaus tekijän mukaan "Östergren J"

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary ﻿

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering rm (ASCOT-LLA): a multi ﻿

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA) ﻿

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) ﻿

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering rm (ASCOT-LLA): a multi

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)